Yunkang Group (HKSE:02325) EBIT : HK$-235.8 Mil (TTM As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Yunkang Group EBIT?

Yunkang Group's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was HK$-113.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-235.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Yunkang Group's annualized ROC % for the quarter that ended in Jun. 2024 was -6.18%. Yunkang Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -16.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Yunkang Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -14.50%.

Yunkang Group EBIT Historical Data

The historical data trend for Yunkang Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yunkang Group EBIT Chart

Yunkang Group Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

2.55

405.45

573.60

517.35

-47.31

Yunkang Group Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial					341.67	191.85	75.28	-122.58	-113.17

Competitive Comparison of Yunkang Group's EBIT

For the Diagnostics & Research subindustry, Yunkang Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yunkang Group's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Yunkang Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Yunkang Group's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Yunkang Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-235.8 Mil.

Yunkang Group (HKSE:02325) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Yunkang Group's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-130.088 * ( 1 - 4.34% )	/	( (2123.183	+	1907.289)	/ 2 )
=	-124.4421808	/	2015.236
=	-6.18 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4957.063	-	1029.527	-	( 2046.163	-	max(0, 2393.878	-	4198.231	+	2046.163	))
=	2123.183

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4381.773	-	967.383	-	( 1507.101	-	max(0, 2101.809	-	3658.153	+	1507.101	))
=	1907.289

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Yunkang Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-226.342	/	( ( (278.512 + max(1021.38, 0))	+	(399.899 + max(1107.4, 0)) )	/	2 )
=	-226.342	/	( ( 1299.892	+	1507.299 )	/	2 )
=	-226.342	/	1403.5955
=	-16.13 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1655.75	+	19.711	+	459.679)	-	(1029.527	+	0	+	84.233)
=	1021.38

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1457.87	+	16.734	+	667.897)	-	(967.383	+	0	+	67.718)
=	1107.4

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Yunkang Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-235.753	/	1625.505
	=	-14.50 %

Yunkang Group EBIT Related Terms

Thank you for viewing the detailed overview of Yunkang Group's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Yunkang Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Yunkang Group Ltd (HKSE:02325) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 6 Yayingshi Road, Science City, Huangpu District, Guangzhou, CHN

Website

http://www.yunkanghealth.com

Yunkang Group Ltd is a medical operation service provider in China. The company has three major business lines namely covering diagnostic testing services for medical consortia, diagnostic outsourcing services, and non-medical institutions.

Executives

Huizekx Limited	2201 Interest of corporation controlled by you
Yk Development Limited	2101 Beneficial owner
Zhang Yong	2201 Interest of corporation controlled by you
Shanghai Pudong Development Bank Co., Ltd	2201 Interest of corporation controlled by you
Kastle Limited	2301 Trustee
Yk Innovation Limited	2301 Trustee
Zhou Xinyu
Guang Zhou Da An Ji Yin Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Da An Guo Ji Ji Tuan You Xian Gong Si	2101 Beneficial owner
Guang Zhou Shi Da An Ji Yin Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Jin Jun Ying Limited	2201 Interest of corporation controlled by you
Mouduans Limited	2201 Interest of corporation controlled by you
Source Capital Rw Limited	2201 Interest of corporation controlled by you
Tongfuzc Limited	2201 Interest of corporation controlled by you
Wjjr Investment Limited	2201 Interest of corporation controlled by you

Yunkang Group Headlines

No Headlines